Anti-MLH1 antibody [4C9C7] (ab76363)
- Product nameAnti-MLH1 antibody [4C9C7]See all MLH1 primary antibodies ...
- DescriptionMouse monoclonal [4C9C7] to MLH1
- Tested applicationsWB, ELISA, IHC-P, Flow Cyt more details
- Species reactivityReacts with: Human
Purified truncated recombinant MBP-MLH1 (corresponding to amino acids 381-483 of Human MLH1) expressed in E.Coli strain BL21 (DE3)
- Positive controlHuman colon and breast carcinoma tissues; Truncated MBP-MLH1 and Trx-MLH1 recombinant proteins.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 0.03% Sodium Azide
- Concentration information loading...
- Clonality Monoclonal
- Clone number4C9C7
- Research Areas
Our Abpromise guarantee covers the use of ab76363 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/500 - 1/2000. Predicted molecular weight: 84 kDa.|
|IHC-P||IHC-P: 1/200 - 1/1000.|
|Flow Cyt||Flow Cyt: 1/100.|
- FunctionHeterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.
- Tissue specificityColon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
- Involvement in diseaseDefects in MLH1 are the cause of hereditary non-polyposis colorectal cancer type 2 (HNPCC2) [MIM:609310]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.
Defects in MLH1 are a cause of mismatch repair cancer syndrome (MMRCS) [MIM:276300]; also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.
Defects in MLH1 are a cause of Muir-Torre syndrome (MuToS) [MIM:158320]; also abbreviated MTS. MuToS is a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.
Note=Defects in MLH1 may contribute to lobular carcinoma in situ (LCIS), a non-invasive neoplastic disease of the breast.
Defects in MLH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
Note=Some epigenetic changes can be transmitted unchanged through the germline (termed 'epigenetic inheritance'). Evidence that this mechanism occurs in humans is provided by the identification of individuals in whom 1 allele of the MLH1 gene is epigenetically silenced throughout the soma (implying a germline event). These individuals are affected by HNPCC but does not have identifiable mutations in MLH1, even though it is silenced, which demonstrates that an epimutation can phenocopy a genetic disease.
- Sequence similaritiesBelongs to the DNA mismatch repair mutL/hexB family.
- Cellular localizationNucleus.
- COCA 2 antibodyCOCA2 antibodyDNA mismatch repair protein Mlh1 antibody
- FCC 2 antibodyFCC2 antibodyhMLH 1 antibodyhMLH1 antibodyHNPCC 2 antibodyHNPCC antibodyHNPCC2 antibodyMGC5172 antibodyMLH 1 antibodyMLH1 antibodyMLH1_HUMAN antibodyMutL homolog 1 (E. coli) antibodyMutL homolog 1 antibodyMutL homolog 1 colon cancer nonpolyposis type 2 antibodyMutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) antibodyMutL protein homolog 1 antibodyMutL, E. coli, homolog of, 1 antibody
Anti-MLH1 antibody [4C9C7] images
All lanes : Anti-MLH1 antibody [4C9C7] (ab76363) at 1/500 dilution
Lane 1 : Truncated MBP-MLH1 recombinant protein
Lane 2 : Truncated Trx-MLH1 (aa381-483) recombinant protein
Predicted band size : 84 kDa
Observed band size : 26,60 kDa (why is the actual band size different from the predicted?)
ab76363 at 1/200 dilution staining MLH1 in human colon carcinoma by Immunohistochemistry using paraffin-embedded tissue with DAB staining showing nuclear location.
ab76363 at 1/200 dilution staining MLH1 in human breast carcinoma by Immunohistochemistry using paraffin-embedded tissue with DAB staining showing nuclear location.
Overlay histogram showing HeLa cells stained with ab76363 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab76363, 1/100 diluton) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HeLa cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.
References for Anti-MLH1 antibody [4C9C7] (ab76363)
ab76363 has not yet been referenced specifically in any publications.